The Street is reporting a surge in cannabis company stocks at the close of trading yesterday following a report in the NY Post titled “Scientists believe that cannabis could help prevent and treat coronavirus.”
The Post is referring to research published online April 19th of this year saying that selectively grown strains of cannabis high in CBD and low in THC can prevent the virus from entering human cells. As we reported yesterday, the researchers say the cannabis decreased viral entry “by … 70 per cent, so it means the level of entry will be restricted. So, therefore, you have more chance to fight it.”
That alone is huge but if you dig through the research you’ll find other nuggets that make it particularly attractive:
This is the Big One – their work could apply to other viruses as well: “Our results lay a foundation for further in-depth analysis of the effects of C. sativa on … COVID-19, as well as other viral diseases in which viruses use the [same] molecular gateway.”
You won’t need a prescription: Because the cells targeted by the coronavirus are quite accessible – in the mouth, airways and intestines – the researchers want to develop inexpensive and easy-to-use CBD-infused mouthwash, inhalers, oils and capsules for both clinic and at-home treatment.
US federal law won’t get in the way: 7 of the 13 strains that kept the virus out of the cells had THC levels less than the federal limit of 0.3% thus qualifying the 7 strains as hemp, not marijuana (which is still illegal under federal law in the US), thereby allowing those strains to be sold OTC at US retail outlets.
Note, however, that as promising as this research is, the scientists counsel caution as their investigations are at the preclinical stage – they tested the cannabis on human tissue grown in the lab.
We looked at their research yesterday including its limitations and posted this article.